Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R; MOMENTUM Study Investigators. Verstovsek S, et al. Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0. Lancet. 2023. PMID: 36709073 Clinical Trial.
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC, Magen H, Lavi N, Gatt ME, Chubar E, Horowitz N, Kreiniz N, Tadmor T, Trestman S, Vitkon R, Rouvio O, Shvetz O, Shaulov A, Ziv-Baran T, Avivi I. Cohen YC, et al. Among authors: kreiniz n. Ann Hematol. 2020 Jun;99(6):1273-1281. doi: 10.1007/s00277-020-03985-9. Epub 2020 Mar 20. Ann Hematol. 2020. PMID: 32193630
The enigma of LAG3 receptor in hematological malignancies.
Kreiniz N, Polliack A, Tadmor T. Kreiniz N, et al. Leuk Lymphoma. 2022 Dec;63(13):3019-3020. doi: 10.1080/10428194.2022.2133543. Epub 2022 Oct 25. Leuk Lymphoma. 2022. PMID: 36282678 No abstract available.
Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial.
Lee JW, Griffin M, Kim JS, Lee Lee LW, Piatek C, Nishimura JI, Carrillo Infante C, Jain D, Liu P, Filippov G, Sicre de Fontbrune F, Risitano A, Kulasekararaj AG; ALXN2040-PNH-301 Investigators. Lee JW, et al. Lancet Haematol. 2023 Dec;10(12):e955-e965. doi: 10.1016/S2352-3026(23)00315-0. Lancet Haematol. 2023. PMID: 38030318 Clinical Trial.
Understanding high-risk smoldering multiple myeloma.
Kreiniz N, Gertz MA. Kreiniz N, et al. Leuk Lymphoma. 2023 Jul-Aug;64(8):1361-1372. doi: 10.1080/10428194.2023.2216818. Epub 2023 May 25. Leuk Lymphoma. 2023. PMID: 37229535 Review.
14 results